Physician profile
Peter H Lu
NPI 1891883104
$3,712.73
in general payments reported to CMS, 2019-2025
28 companies · $595 in 2025
The $595 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $346 · 2021: $580 · 2022: $456 · 2023: $926 · 2024: $437 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,436.11 | 2020-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $326.99 | 2019-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $320.74 | 2020-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $317.76 | 2021-2025 | Tepezza, Evenity, Repatha |
| Insulet Corporation | $255.63 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $145.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $126.66 | 2020-2023 | |
| Astrazeneca Pharmaceuticals Lp | $116.03 | 2019-2021 | |
| Beta Bionics, INC. | $111.61 | 2023 | Ilet Bionic Pancreas |
| Medtronic Minimed, INC. | $89.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.61 | 2023-2025 | Synjardy, Jardiance, Tradjenta |
| Amneal Pharmaceuticals LLC | $49.73 | 2021-2024 | Unithroid |
| Medtronic, INC. | $40.77 | 2021-2022 | |
| Horizon Therapeutics Plc | $40.75 | 2023 | Tepezza |
| Ferring Pharmaceuticals INC. | $36.89 | 2025 | Menopur |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.63 | 2022 | |
| Sanofi-Aventis U.S. LLC | $29.11 | 2019-2022 | |
| Senseonics, Incorporated | $23.00 | 2019 | |
| Abbvie INC. | $22.89 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.35 | 2019 | |
| Eisai INC. | $17.14 | 2020 | |
| Lilly USA, LLC | $16.82 | 2025 | Jardiance |
| Roche Diabetes Care, INC. | $14.49 | 2021 | |
| Silk Road Medical, INC. | $14.47 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Corcept Therapeutics | $14.39 | 2024 | Korlym |
| Antares Pharma, INC. | $14.15 | 2021 | |
| Ascendis Pharma Endocrinology INC | $13.78 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.